Mesoblast Ltd (ASX: MSB) shares are edging lower despite the biotech company delivering another upbeat commercial update today.
In early afternoon trade, the Mesoblast share price is down 0.47% to $2.12. By comparison, the S&P/ASX 200 Index (ASX: XJO) is hovering 1.5% higher to 8,696 points.
The weaker move for Mesoblast suggests the market may now be waiting for the next bigger catalyst after the stock's strong recovery over the past year.
Here's what the market is weighing up.
Image source: Getty Images
Ryoncil keeps building momentum
According to today's update, Mesoblast's flagship cell therapy Ryoncil generated net sales of US$30.3 million during the March quarter.
Management said this completed the product's first full-year launch cycle. Growth in February and March more than offset the usual seasonal weakness seen in January.
That puts cumulative net revenue since launch close to US$100 million, a major commercial milestone for a company that spent years working toward US commercialisation.
Ryoncil remains Mesoblast's first FDA-approved product and is currently approved in the United States for steroid-refractory acute graft-versus-host disease in children.
The company said the product's profitability is helping fund its broader late-stage pipeline. This includes label expansion studies and other inflammatory disease programs.
Why the market may still be cautious
Even with the positive sales result, the share price reaction has remained low-key.
Part of that likely reflects how much optimism had already been priced in earlier this year when Mesoblast shares hit a 52-week high above $3.30 in January.
At $2.12, the stock is now trading well below that level, even as operating progress continues.
The company's market capitalisation still sits near $2.75 billion, showing investors still see considerable value in the rest of its pipeline.
The softer move today may also reflect the fact that this release focused on quarterly sales progress rather than upgraded guidance, regulatory milestones, or new clinical data.
After such a strong run in recent quarters, the market may now be waiting for the next major clinical or commercial update before bidding the shares higher again.
What to watch next
The next major watch point is whether Mesoblast can keep quarterly sales growth building toward its previously guided FY2026 Ryoncil net revenue range of US$110 million to US$120 million.
If sales momentum continues, attention is likely to shift toward margin improvement, cash generation, and progress across its late-stage pipeline.
Despite today's positive update, Mesoblast shares are down roughly 21% since the start of the year.
